As Vice President of High-throughput Biology Aj is responsible for producing high-quality data sets to use in for machine learning-based target and drug discovery. He leads insitro’s wet lab activities (bio-data factory) which consists of functional genomic, disease modeling, automation/process engineering and proteomic teams.
Ajamete has spent over 28 years in both industry and academia, working in the areas of proteomics, genomics, and stem cell biology. Before joining insitro, Aj led the early target discovery team at Novartis Institutes for Biomedical Research in the Neuroscience unit. His team efforts have led to the discovery of multiple new disease targets and the development of better predictive preclinical models. He conducted his postdoc with Dr. Randy Moon at University of Washington/Howard Hughes Medical Institute on Wnt-signaling. While in Randy’s lab, he conducted one of the first ever genome-wide RNAi screens and studied the role of Wnt-signaling in human disease and stem cell biology. He did his graduate work at University of Wisconsin-Madison in Dr. Bill Sugden’s lab where he studied virology, immunology, and oncology.
In his free time, Aj enjoys traveling, kayaking, sailing, biking, making whiskey and most of all his family.
Selected Publications:DRUG-seq: A Miniaturized High-Throughput Transcriptome Profiling Platform for Drug Discovery. Ye C, Ho DJ, Neri M, Yang C, Kulkarni T, Randhawa R, Henault M, Mostacci N, Farmer P, Renner S, Ihry R, Mansur L, Gubser Keller C, McAllister G, Hild M, Jenkins J, and Kaykas A. In Press, Sept; 2018 Nat. Comm. https://www.nature.com/articles/s41467-018-06500-x p53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells. Ihry RJ, Worringer KA, Salick MR, Frias E, Ho D, Theriault K, Kommineni S, Chen J, Sondey M, Ye C, Randhawa R, Kulkarni T, Yang Z, McAllister G, Russ C, Reece-Hoyes J, Forrester W, Hoffman GR, Dolmetsch R, Kaykas A. Nat Med. 2018 Jul;24(7):939-946. https://www.nature.com/articles/s41591-018-0050-6 A Single-Cell Roadmap of Lineage Bifurcation in Human ESC Models of Embryonic Brain Development. Yao Z, Mich JK, Ku S, Menon V, Krostag AR, Martinez RA, Furchtgott L, Mulholland H, Bort S, Fuqua MA, Gregor BW, Hodge RD, Jayabalu A, May RC, Melton S, Nelson AM, Ngo NK, Shapovalova NV, Shehata SI, Smith MW, Tait LJ, Thompson CL, Thomsen ER, Ye C, Glass IA, Kaykas A, Yao S, Phillips JW, Grimley JS, Levi BP, Wang Y, Ramanathan S. Cell Stem Cell. 2017 Jan 5;20(1) https://www.cell.com/cell-stem-cell/fulltext/S1934-5909(16)30340-X?code=cell-site Genetic Ablation of AXL Does Not Protect Human Neural Progenitor Cells and Cerebral Organoids from Zika Virus Infection. Wells MF, Salick MR, Wiskow O, Ho DJ, Worringer KA, Ihry RJ, Kommineni S, Bilican B, Klim JR, Hill EJ, Kane LT, Ye C, Kaykas A*, Eggan K.* Cell Stem Cell. 2016 Dec 1;19(6):703-708. *Co-corresponding author https://www.cell.com/cell-stem-cell/fulltext/S1934-5909(16)30407-6 Functional genomic analysis of the Wnt-wingless signaling pathway. DasGupta R*, Kaykas A*, Moon RT, Perrimon N. Science. 2005 May 6;308(5723):826-33. *Co-first authors https://science.sciencemag.org/content/308/5723/826
Britt Huber is the Vice President of People at insitro. She brings with her over 15 years of experience in People Operations / Human Resources, Organizational Development and business management leadership roles, in
the life sciences and technology industries, both in California and in Switzerland. Britt is passionate about developing mission-driven companies and coaching its people to evoke excellence.
Prior to joining insitro, Britt served as VP, People & Organizational Development at PaxVax, Inc., a fully-integrated specialty vaccines company, which she helped build and scale from start-up to a global, commercial stage company that was acquired by Emergent BioSolutions in 2018. Before then, Britt was the VP of People at Kiva, the world’s first personal micro-lending platform, where she supported the organization’s doubling in size, internationalization, and creation of an awesome culture.
Britt holds an MBA from St. Mary’s College, Moraga, California and a Senior Professional in Human Resources (SPHR)-Certification. She’s also a Certified Professional Coach from New Ventures West, San Francisco, California. She speaks English, German, French, Italian, and Spanish.
When Britt is not cheer-leading the people she serves, she loves to explore the world traveling, enjoys the great outdoors while running, biking, hiking, swimming, skating,painting or striking a yoga pose somewhere.
Daphne Koller is the CEO and Founder of insitro.
Daphne was the Rajeev Motwani Professor of Computer Science at Stanford University, where she served on the faculty for 18 years. She was the co-founder, co-CEO and President of Coursera for 5 years, and the Chief Computing Officer of Calico, an Alphabet company in the healthcare space. She is the author of over 200 refereed publications appearing in venues such as Science, Cell, and Nature Genetics, and has an h-index of 130. Daphne was one of TIME Magazine’s 100 most influential people and is a MacArthur Fellow, a member of the National Academy of Engineering, and a Fellow of the American Academy of Arts and Sciences and the International Society of Computational Biology.
In her spare time, Daphne enjoys spending time with her family, especially while traveling to exotic destinations (62 countries so far and counting), where they enjoy hiking, sailing, scuba diving, and eating fresh local food.
Jason is responsible for building and optimizing insitro’s Research Operations function. He also manages insitro’s internal discovery programs as well as partnered programs with external collaborators.
Prior to joining insitro, Jason spent 15 years at the Novartis Institutes for BioMedical Research in both Oncology and Infectious Diseases groups. His roles spanned portfolio strategy, program management, and scientific operations. During his time in Oncology, Jason helped lead the team that discovered and developed Encorafenib, approved as BRAFTOVI for the treatment of B-Raf mutant melanoma. Prior to NIBR, Jason worked for McKinsey & Company serving primarily Boston area biotech companies. He earned his PhD in Oncology from The Johns Hopkins University School of Medicine.
Jason enjoys the balance of Art with Science and TIG welds steel sculptures.
Dr. Jason Coloma is the CEO of Maze Therapeutics, a company translating novel genetic insights into lifesaving medicines, through an approach that integrates human genetics and functional genomics. Prior to his appointment to CEO, he was Maze’s interim chief operating officer and a venture partner at Third Rock Ventures, where he was instrumental in the founding and launch of the company. As a venture partner at Third Rock, Jason focused on new company creation, and held interim chief business officer roles at insitro and Celsius Therapeutics.
Prior to Third Rock, Jason was senior vice president and chief business officer at Corvus Pharmaceuticals. Previously, he held a number of roles at Roche, including vice president & global therapeutic area head of oncology and cancer immunotherapy partnering. Before joining Roche, Jason was a consultant in the life sciences practice at L.E.K. Consulting. He also worked in finance at Amgen and in research at the University of California, San Francisco and Cytokinetics.
Jason holds a Ph.D. and M.P.H. at the University of California, Berkeley, an MBA from the Tuck School of Business at Dartmouth and a B.S. in biology from the University of San Francisco.
As the Head of Process Engineering, John is responsible for leading the development and deployment of lab automation for high-throughput, effective production of high-quality data sets to use in machine learning. John’s team also will focus on building out the tools and capabilities for implementing operational excellence across all of insitro’s laboratories.
Prior to joining insitro, John spent the last 20 years designing, building and managing automation solutions across biotech and pharmaceutical industries. He has significant expertise with early-stage startups, helping to develop, implement and support automation technologies as they scale. John has an M.Eng. in Systems Engineering from Penn State University.
He is an avid outdoor enthusiast who enjoys backpacking, road biking, landscape photography, and travel.
As Senior Vice-President of Drug Discovery, Keith is responsible for machine learning-enabled drug discovery programs at insitro. Keith and his team are both establishing new drug design capabilities, exploiting the power of machine learning models, and undertaking drug discovery programs on molecular targets derived via the insitro-human (ISH) target discovery platform.
Keith has over three decades of drug discovery experience, building and leading research enterprises ranging from handfuls to hundreds of scientists, tackling programs across a wide range of therapeutic areas, and employing a panoply of therapeutic modalities. During his career, Keith, and the organizations he has led, have delivered over thirty clinical candidates, across fifteen therapeutic areas, many of which have reached Phase 2, and two of which are in the hands of physicians treating patients today – eletriptan (Relpax®) for migraines and maraviroc (Selzentry®) for HIV infections.
Before joining insitro, Keith was President of the Ferring Research Institute in San Diego, engaged in the discovery of peptide therapeutics. Before joining Ferring, Keith had a long career at Pfizer, leading discovery research at three different sites across the US and UK, heading the company’s R&D strategy team, and running a laboratory as a visiting investigator at The Scripps Research Institute.
Keith completed his academic and postdoctoral studies at Imperial College London, The University of Cambridge (Raphael lab), Stanford University (Johnson lab), and Columbia University (Stork lab).
In his free time, Keith enjoys cycling, jogging, reading, writing and mechanical watches.
Matthew Albert is Vice President of Immunology & Infectious Diseases at insitro.
Prior to joining insitro, Matthew worked as Principal Scientist in the Department of Cancer Immunology at Genentech (2015 – 2019); and served as Professor (2003 – 2015), Founder and Director of the Center for Human Immunology (2007 – 2015) and Director of the Immunology Department at Institut Pasteur, Paris France (2010 – 2015).
Matthew is an immunologist and clinical pathologist, with a long-standing interest in immune regulation and tumor immunity. His research embraces the power of a “human-first” approach to scientific discovery, driven by a commitment to understand how to achieve effective response to cancer immunotherapy, autoimmunity and chronic infection while limiting adverse effects of treatment. As this requires a deep insight into health and disease pathogenesis, he has developed several areas of investigation over the last two decades, which has included a deep commitment to bladder diseases (incl. cancer and UTI); and liver diseases (incl. HCV, HBV, HCC and NASH). He has also been a leader in the Milieu Intérieur Consortium, a 30-team academic / industrial partnership that aims to define the genetic, microbiome and environmental determinants of variable immune responses in healthy persons.
Matthew trained at The Rockefeller University, Cornell University Medical College and did his residency at New York Presbyterian Hospital. He is the author of more than 100 peer-reviewed scientific papers and has made major contributions to the understanding of antigen cross-priming and the impact of post-translational modification of chemokines as determinants of effective tumor immunity. In his spare time, he and his family enjoy cooking together, traveling and exploring the world’s ecology under the sea (marvelling at Ostracod mating practices in the Carribean), in jungles (visits to the Sarawak Biodiversity Centre in Borneo), and in ecology parks (riding dolphins in Tunisia). The have traveled together to over 35 countries, with a strong belief that knowing and engaging with diverse communities and cultures help them be better contributors to the world.
Selected Publications:Germline genetic polymorphisms influence tumor gene expression and immune cell infiltration. Lim YW, Chen-Harris H, Mayba O, Lianoglou S, Wuster A, Bhangale T, Khan Z, Mariathasan S, Daemen A, Reeder J, Haverty PM, Forrest WF, Brauer M, Mellman I, Albert ML. Proc Natl Acad Sci U S A. 2018 Dec 11;115(50):E11701-E11710. doi: 10.1073/pnas.1804506115. Epub 2018 Nov 21 Natural variation in the parameters of innate immune cells is preferentially driven by genetic factors. Patin E, Hasan M, Bergstedt J, Rouilly V, Libri V, Urrutia A, Alanio C, Scepanovic P, Hammer C, Jönsson F, Beitz B, Quach H, Lim YW, Hunkapiller J, Zepeda M, Green C, Piasecka B, Leloup C, Rogge L, Huetz F, Peguillet I, Lantz O, Fontes M, Di Santo JP, Thomas S, Fellay J, Duffy D, Quintana-Murci L, Albert ML; Milieu Intérieur Consortium. Nat Immunol. 2018 Mar;19(3):302-314. doi: 10.1038/s41590-018-0049-7. Epub 2018 Feb 23 Genetic Adaptation and Neandertal Admixture Shaped the Immune System of Human Populations. Quach H, Rotival M, Pothlichet J, Loh YE, Dannemann M, Zidane N, Laval G, Patin E, Harmant C, Lopez M, Deschamps M, Naffakh N, Duffy D, Coen A, Leroux-Roels G, Clément F, Boland A, Deleuze JF, Kelso J, Albert ML, Quintana-Murci L. Cell. 2016 Oct 20;167(3):643-656.e17. doi: 10.1016/j.cell.2016.09.024 RIPK1 and NF-κB signaling in dying cells determines cross-priming of CD8⁺ T cells. Yatim N, Jusforgues-Saklani H, Orozco S, Schulz O, Barreira da Silva R, Reis e Sousa C, Green DR, Oberst A, Albert ML. Science. 2015 Oct 16;350(6258):328-34. doi: 10.1126/science.aad0395. Epub 2015 Sep 24